Premium
Systematic review: the chemoprevention of oesophageal adenocarcinoma
Author(s) -
MEHTA S.,
JOHNSON I. T.,
RHODES M.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02667.x
Subject(s) - medicine , metaplasia , adenocarcinoma , malignancy , disease , cancer , gastroenterology , oncology , cancer research
Summary The incidence of oesophageal adenocarcinoma is increasing in the UK faster than any other malignancy. Despite its relatively poor prognosis and the limited success of existing treatments, there is enthusiasm that chemopreventive agents might be able to stem the transition from normal squamous epithelium to adenocarcinoma. We discuss gastro‐oesophageal reflux as the main risk factor for the development of Barrett's metaplasia, the only known precursor of oesophageal adenocarcinoma. Treatment options for reflux disease are considered with regard to their effects on cancer risk. Recent advances in the molecular and cell biology of Barrett's are outlined, and potential targets for chemoprevention examined. Available treatments for reflux disease have not convincingly altered the likelihood of cancer development. Epidemiological and animal studies support the use of non‐steroidal anti‐inflammatory drugs as potential chemopreventive agents. Dietary agents, however, have a more favourable side‐effect profile and may prove to be an attractive alternative, although more work is needed to fully explore this prospect.